Cannabinoid Drugs Comprehensive Study by Type (Phytocannabinoids, Endocannabinoids, Synthetics), Application (Chronic Diseases, Anxiety, Nausea, Others), End-users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2032

Report Objectives / Segmentation Covered

• Phytocannabinoids
• Endocannabinoids
• Synthetics

• Chronic Diseases
• Anxiety
• Nausea
• Others

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • Italy
  • United Kingdom
  • Netherlands
  • Rest of Europe
• MEA
  • Middle East
  • Africa
• North America
  • United States
  • Canada
  • Mexico

• 1. Market Overview
  • 1.1. Introduction
  • 1.2. Scope/Objective of the Study
    • 1.2.1. Research Objective
• 2. Executive Summary
  • 2.1. Introduction
• 3. Market Dynamics
  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Increasing Prevalence of Chronic Diseases
    • 3.2.2. Increased Legalization of Cannabinoid
  • 3.3. Market Challenges
    • 3.3.1. Stringent Government Rules and Regulations
  • 3.4. Market Trends
    • 3.4.1. Increased Research and Development Activities on Cannabinoid Drugs Applications
• 4. Market Factor Analysis
  • 4.1. Porters Five Forces
  • 4.2. Supply/Value Chain
  • 4.3. PESTEL analysis
  • 4.4. Market Entropy
  • 4.5. Patent/Trademark Analysis
• 5. Global Cannabinoid Drugs, by Type, Application, End-users, Distribution Channel and Region (value, volume and price ) (2019-2024)
  • 5.1. Introduction
  • 5.2. Global Cannabinoid Drugs (Value)
    • 5.2.1. Global Cannabinoid Drugs by: Type (Value)
      • 5.2.1.1. Phytocannabinoids
      • 5.2.1.2. Endocannabinoids
      • 5.2.1.3. Synthetics
    • 5.2.2. Global Cannabinoid Drugs by: Application (Value)
      • 5.2.2.1. Chronic Diseases
      • 5.2.2.2. Anxiety
      • 5.2.2.3. Nausea
      • 5.2.2.4. Others
    • 5.2.3. Global Cannabinoid Drugs by: End-users (Value)
      • 5.2.3.1. Hospitals
      • 5.2.3.2. Clinics
      • 5.2.3.3. Ambulatory Surgical Centers
      • 5.2.3.4. Others
    • 5.2.4. Global Cannabinoid Drugs by: Distribution Channel (Value)
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Retail Pharmacies
      • 5.2.4.3. Online Pharmacies
    • 5.2.5. Global Cannabinoid Drugs Region
      • 5.2.5.1. South America
        • 5.2.5.1.1. Brazil
        • 5.2.5.1.2. Argentina
        • 5.2.5.1.3. Rest of South America
      • 5.2.5.2. Asia Pacific
        • 5.2.5.2.1. China
        • 5.2.5.2.2. Japan
        • 5.2.5.2.3. India
        • 5.2.5.2.4. South Korea
        • 5.2.5.2.5. Taiwan
        • 5.2.5.2.6. Australia
        • 5.2.5.2.7. Rest of Asia-Pacific
      • 5.2.5.3. Europe
        • 5.2.5.3.1. Germany
        • 5.2.5.3.2. France
        • 5.2.5.3.3. Italy
        • 5.2.5.3.4. United Kingdom
        • 5.2.5.3.5. Netherlands
        • 5.2.5.3.6. Rest of Europe
      • 5.2.5.4. MEA
        • 5.2.5.4.1. Middle East
        • 5.2.5.4.2. Africa
      • 5.2.5.5. North America
        • 5.2.5.5.1. United States
        • 5.2.5.5.2. Canada
        • 5.2.5.5.3. Mexico
  • 5.3. Global Cannabinoid Drugs (Volume)
    • 5.3.1. Global Cannabinoid Drugs by: Type (Volume)
      • 5.3.1.1. Phytocannabinoids
      • 5.3.1.2. Endocannabinoids
      • 5.3.1.3. Synthetics
    • 5.3.2. Global Cannabinoid Drugs by: Application (Volume)
      • 5.3.2.1. Chronic Diseases
      • 5.3.2.2. Anxiety
      • 5.3.2.3. Nausea
      • 5.3.2.4. Others
    • 5.3.3. Global Cannabinoid Drugs by: End-users (Volume)
      • 5.3.3.1. Hospitals
      • 5.3.3.2. Clinics
      • 5.3.3.3. Ambulatory Surgical Centers
      • 5.3.3.4. Others
    • 5.3.4. Global Cannabinoid Drugs by: Distribution Channel (Volume)
      • 5.3.4.1. Hospital Pharmacies
      • 5.3.4.2. Retail Pharmacies
      • 5.3.4.3. Online Pharmacies
    • 5.3.5. Global Cannabinoid Drugs Region
      • 5.3.5.1. South America
        • 5.3.5.1.1. Brazil
        • 5.3.5.1.2. Argentina
        • 5.3.5.1.3. Rest of South America
      • 5.3.5.2. Asia Pacific
        • 5.3.5.2.1. China
        • 5.3.5.2.2. Japan
        • 5.3.5.2.3. India
        • 5.3.5.2.4. South Korea
        • 5.3.5.2.5. Taiwan
        • 5.3.5.2.6. Australia
        • 5.3.5.2.7. Rest of Asia-Pacific
      • 5.3.5.3. Europe
        • 5.3.5.3.1. Germany
        • 5.3.5.3.2. France
        • 5.3.5.3.3. Italy
        • 5.3.5.3.4. United Kingdom
        • 5.3.5.3.5. Netherlands
        • 5.3.5.3.6. Rest of Europe
      • 5.3.5.4. MEA
        • 5.3.5.4.1. Middle East
        • 5.3.5.4.2. Africa
      • 5.3.5.5. North America
        • 5.3.5.5.1. United States
        • 5.3.5.5.2. Canada
        • 5.3.5.5.3. Mexico
  • 5.4. Global Cannabinoid Drugs (Price)
    • 5.4.1. Global Cannabinoid Drugs by: Type (Price)
• 6. Cannabinoid Drugs: Manufacturers/Players Analysis
  • 6.1. Competitive Landscape
    • 6.1.1. Market Share Analysis
      • 6.1.1.1. Top 3
      • 6.1.1.2. Top 5
  • 6.2. Peer Group Analysis (2024)
  • 6.3. BCG Matrix
  • 6.4. Company Profile
    • 6.4.1. Echo Pharmaceuticals B.V. (Netherlands)
      • 6.4.1.1. Business Overview
      • 6.4.1.2. Products/Services Offerings
      • 6.4.1.3. Financial Analysis
      • 6.4.1.4. SWOT Analysis
    • 6.4.2. Mandara Pharma (Canada)
      • 6.4.2.1. Business Overview
      • 6.4.2.2. Products/Services Offerings
      • 6.4.2.3. Financial Analysis
      • 6.4.2.4. SWOT Analysis
    • 6.4.3. GW Pharmaceuticals, plc (United Kingdom)
      • 6.4.3.1. Business Overview
      • 6.4.3.2. Products/Services Offerings
      • 6.4.3.3. Financial Analysis
      • 6.4.3.4. SWOT Analysis
    • 6.4.4. Nexien BioPharma (United States)
      • 6.4.4.1. Business Overview
      • 6.4.4.2. Products/Services Offerings
      • 6.4.4.3. Financial Analysis
      • 6.4.4.4. SWOT Analysis
    • 6.4.5. BOL Pharma (Israel)
      • 6.4.5.1. Business Overview
      • 6.4.5.2. Products/Services Offerings
      • 6.4.5.3. Financial Analysis
      • 6.4.5.4. SWOT Analysis
    • 6.4.6. CURE Pharmaceutical Holding Corp. (United States)
      • 6.4.6.1. Business Overview
      • 6.4.6.2. Products/Services Offerings
      • 6.4.6.3. Financial Analysis
      • 6.4.6.4. SWOT Analysis
    • 6.4.7. RAMM Pharma (Canada)
      • 6.4.7.1. Business Overview
      • 6.4.7.2. Products/Services Offerings
      • 6.4.7.3. Financial Analysis
      • 6.4.7.4. SWOT Analysis
    • 6.4.8. Greenwich Biosciences, Inc. (United States)
      • 6.4.8.1. Business Overview
      • 6.4.8.2. Products/Services Offerings
      • 6.4.8.3. Financial Analysis
      • 6.4.8.4. SWOT Analysis
    • 6.4.9. UNIVO Pharmaceuticals (Israel)
      • 6.4.9.1. Business Overview
      • 6.4.9.2. Products/Services Offerings
      • 6.4.9.3. Financial Analysis
      • 6.4.9.4. SWOT Analysis
    • 6.4.10. InMed Pharmaceuticals (Canada)
      • 6.4.10.1. Business Overview
      • 6.4.10.2. Products/Services Offerings
      • 6.4.10.3. Financial Analysis
      • 6.4.10.4. SWOT Analysis
    • 6.4.11. Abbott Laboratories (United States)
      • 6.4.11.1. Business Overview
      • 6.4.11.2. Products/Services Offerings
      • 6.4.11.3. Financial Analysis
      • 6.4.11.4. SWOT Analysis
• 7. Global Cannabinoid Drugs Sale, by Type, Application, End-users, Distribution Channel and Region (value, volume and price ) (2027-2032)
  • 7.1. Introduction
  • 7.2. Global Cannabinoid Drugs (Value)
    • 7.2.1. Global Cannabinoid Drugs by: Type (Value)
      • 7.2.1.1. Phytocannabinoids
      • 7.2.1.2. Endocannabinoids
      • 7.2.1.3. Synthetics
    • 7.2.2. Global Cannabinoid Drugs by: Application (Value)
      • 7.2.2.1. Chronic Diseases
      • 7.2.2.2. Anxiety
      • 7.2.2.3. Nausea
      • 7.2.2.4. Others
    • 7.2.3. Global Cannabinoid Drugs by: End-users (Value)
      • 7.2.3.1. Hospitals
      • 7.2.3.2. Clinics
      • 7.2.3.3. Ambulatory Surgical Centers
      • 7.2.3.4. Others
    • 7.2.4. Global Cannabinoid Drugs by: Distribution Channel (Value)
      • 7.2.4.1. Hospital Pharmacies
      • 7.2.4.2. Retail Pharmacies
      • 7.2.4.3. Online Pharmacies
    • 7.2.5. Global Cannabinoid Drugs Region
      • 7.2.5.1. South America
        • 7.2.5.1.1. Brazil
        • 7.2.5.1.2. Argentina
        • 7.2.5.1.3. Rest of South America
      • 7.2.5.2. Asia Pacific
        • 7.2.5.2.1. China
        • 7.2.5.2.2. Japan
        • 7.2.5.2.3. India
        • 7.2.5.2.4. South Korea
        • 7.2.5.2.5. Taiwan
        • 7.2.5.2.6. Australia
        • 7.2.5.2.7. Rest of Asia-Pacific
      • 7.2.5.3. Europe
        • 7.2.5.3.1. Germany
        • 7.2.5.3.2. France
        • 7.2.5.3.3. Italy
        • 7.2.5.3.4. United Kingdom
        • 7.2.5.3.5. Netherlands
        • 7.2.5.3.6. Rest of Europe
      • 7.2.5.4. MEA
        • 7.2.5.4.1. Middle East
        • 7.2.5.4.2. Africa
      • 7.2.5.5. North America
        • 7.2.5.5.1. United States
        • 7.2.5.5.2. Canada
        • 7.2.5.5.3. Mexico
  • 7.3. Global Cannabinoid Drugs (Volume)
    • 7.3.1. Global Cannabinoid Drugs by: Type (Volume)
      • 7.3.1.1. Phytocannabinoids
      • 7.3.1.2. Endocannabinoids
      • 7.3.1.3. Synthetics
    • 7.3.2. Global Cannabinoid Drugs by: Application (Volume)
      • 7.3.2.1. Chronic Diseases
      • 7.3.2.2. Anxiety
      • 7.3.2.3. Nausea
      • 7.3.2.4. Others
    • 7.3.3. Global Cannabinoid Drugs by: End-users (Volume)
      • 7.3.3.1. Hospitals
      • 7.3.3.2. Clinics
      • 7.3.3.3. Ambulatory Surgical Centers
      • 7.3.3.4. Others
    • 7.3.4. Global Cannabinoid Drugs by: Distribution Channel (Volume)
      • 7.3.4.1. Hospital Pharmacies
      • 7.3.4.2. Retail Pharmacies
      • 7.3.4.3. Online Pharmacies
    • 7.3.5. Global Cannabinoid Drugs Region
      • 7.3.5.1. South America
        • 7.3.5.1.1. Brazil
        • 7.3.5.1.2. Argentina
        • 7.3.5.1.3. Rest of South America
      • 7.3.5.2. Asia Pacific
        • 7.3.5.2.1. China
        • 7.3.5.2.2. Japan
        • 7.3.5.2.3. India
        • 7.3.5.2.4. South Korea
        • 7.3.5.2.5. Taiwan
        • 7.3.5.2.6. Australia
        • 7.3.5.2.7. Rest of Asia-Pacific
      • 7.3.5.3. Europe
        • 7.3.5.3.1. Germany
        • 7.3.5.3.2. France
        • 7.3.5.3.3. Italy
        • 7.3.5.3.4. United Kingdom
        • 7.3.5.3.5. Netherlands
        • 7.3.5.3.6. Rest of Europe
      • 7.3.5.4. MEA
        • 7.3.5.4.1. Middle East
        • 7.3.5.4.2. Africa
      • 7.3.5.5. North America
        • 7.3.5.5.1. United States
        • 7.3.5.5.2. Canada
        • 7.3.5.5.3. Mexico
  • 7.4. Global Cannabinoid Drugs (Price)
    • 7.4.1. Global Cannabinoid Drugs by: Type (Price)
• 8. Appendix
  • 8.1. Acronyms
• 9. Methodology and Data Source
  • 9.1. Methodology/Research Approach
    • 9.1.1. Research Programs/Design
    • 9.1.2. Market Size Estimation
    • 9.1.3. Market Breakdown and Data Triangulation
  • 9.2. Data Source
    • 9.2.1. Secondary Sources
    • 9.2.2. Primary Sources
  • 9.3. Disclaimer

• Table 1. Cannabinoid Drugs: by Type(USD Million)
• Table 2. Cannabinoid Drugs Phytocannabinoids , by Region USD Million (2019-2024)
• Table 3. Cannabinoid Drugs Endocannabinoids , by Region USD Million (2019-2024)
• Table 4. Cannabinoid Drugs Synthetics , by Region USD Million (2019-2024)
• Table 5. Cannabinoid Drugs: by Application(USD Million)
• Table 6. Cannabinoid Drugs Chronic Diseases , by Region USD Million (2019-2024)
• Table 7. Cannabinoid Drugs Anxiety , by Region USD Million (2019-2024)
• Table 8. Cannabinoid Drugs Nausea , by Region USD Million (2019-2024)
• Table 9. Cannabinoid Drugs Others , by Region USD Million (2019-2024)
• Table 10. Cannabinoid Drugs: by End-users(USD Million)
• Table 11. Cannabinoid Drugs Hospitals , by Region USD Million (2019-2024)
• Table 12. Cannabinoid Drugs Clinics , by Region USD Million (2019-2024)
• Table 13. Cannabinoid Drugs Ambulatory Surgical Centers , by Region USD Million (2019-2024)
• Table 14. Cannabinoid Drugs Others , by Region USD Million (2019-2024)
• Table 15. Cannabinoid Drugs: by Distribution Channel(USD Million)
• Table 16. Cannabinoid Drugs Hospital Pharmacies , by Region USD Million (2019-2024)
• Table 17. Cannabinoid Drugs Retail Pharmacies , by Region USD Million (2019-2024)
• Table 18. Cannabinoid Drugs Online Pharmacies , by Region USD Million (2019-2024)
• Table 19. South America Cannabinoid Drugs, by Country USD Million (2019-2024)
• Table 20. South America Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 21. South America Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 22. South America Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 23. South America Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 24. Brazil Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 25. Brazil Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 26. Brazil Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 27. Brazil Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 28. Argentina Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 29. Argentina Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 30. Argentina Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 31. Argentina Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 32. Rest of South America Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 33. Rest of South America Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 34. Rest of South America Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 35. Rest of South America Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 36. Asia Pacific Cannabinoid Drugs, by Country USD Million (2019-2024)
• Table 37. Asia Pacific Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 38. Asia Pacific Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 39. Asia Pacific Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 40. Asia Pacific Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 41. China Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 42. China Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 43. China Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 44. China Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 45. Japan Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 46. Japan Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 47. Japan Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 48. Japan Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 49. India Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 50. India Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 51. India Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 52. India Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 53. South Korea Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 54. South Korea Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 55. South Korea Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 56. South Korea Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 57. Taiwan Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 58. Taiwan Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 59. Taiwan Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 60. Taiwan Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 61. Australia Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 62. Australia Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 63. Australia Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 64. Australia Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 65. Rest of Asia-Pacific Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 66. Rest of Asia-Pacific Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 67. Rest of Asia-Pacific Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 68. Rest of Asia-Pacific Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 69. Europe Cannabinoid Drugs, by Country USD Million (2019-2024)
• Table 70. Europe Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 71. Europe Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 72. Europe Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 73. Europe Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 74. Germany Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 75. Germany Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 76. Germany Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 77. Germany Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 78. France Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 79. France Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 80. France Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 81. France Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 82. Italy Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 83. Italy Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 84. Italy Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 85. Italy Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 86. United Kingdom Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 87. United Kingdom Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 88. United Kingdom Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 89. United Kingdom Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 90. Netherlands Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 91. Netherlands Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 92. Netherlands Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 93. Netherlands Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 94. Rest of Europe Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 95. Rest of Europe Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 96. Rest of Europe Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 97. Rest of Europe Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 98. MEA Cannabinoid Drugs, by Country USD Million (2019-2024)
• Table 99. MEA Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 100. MEA Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 101. MEA Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 102. MEA Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 103. Middle East Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 104. Middle East Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 105. Middle East Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 106. Middle East Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 107. Africa Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 108. Africa Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 109. Africa Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 110. Africa Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 111. North America Cannabinoid Drugs, by Country USD Million (2019-2024)
• Table 112. North America Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 113. North America Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 114. North America Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 115. North America Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 116. United States Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 117. United States Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 118. United States Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 119. United States Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 120. Canada Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 121. Canada Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 122. Canada Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 123. Canada Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 124. Mexico Cannabinoid Drugs, by Type USD Million (2019-2024)
• Table 125. Mexico Cannabinoid Drugs, by Application USD Million (2019-2024)
• Table 126. Mexico Cannabinoid Drugs, by End-users USD Million (2019-2024)
• Table 127. Mexico Cannabinoid Drugs, by Distribution Channel USD Million (2019-2024)
• Table 128. Cannabinoid Drugs Sales: by Type(K Units)
• Table 129. Cannabinoid Drugs Sales Phytocannabinoids , by Region K Units (2019-2024)
• Table 130. Cannabinoid Drugs Sales Endocannabinoids , by Region K Units (2019-2024)
• Table 131. Cannabinoid Drugs Sales Synthetics , by Region K Units (2019-2024)
• Table 132. Cannabinoid Drugs Sales: by Application(K Units)
• Table 133. Cannabinoid Drugs Sales Chronic Diseases , by Region K Units (2019-2024)
• Table 134. Cannabinoid Drugs Sales Anxiety , by Region K Units (2019-2024)
• Table 135. Cannabinoid Drugs Sales Nausea , by Region K Units (2019-2024)
• Table 136. Cannabinoid Drugs Sales Others , by Region K Units (2019-2024)
• Table 137. Cannabinoid Drugs Sales: by End-users(K Units)
• Table 138. Cannabinoid Drugs Sales Hospitals , by Region K Units (2019-2024)
• Table 139. Cannabinoid Drugs Sales Clinics , by Region K Units (2019-2024)
• Table 140. Cannabinoid Drugs Sales Ambulatory Surgical Centers , by Region K Units (2019-2024)
• Table 141. Cannabinoid Drugs Sales Others , by Region K Units (2019-2024)
• Table 142. Cannabinoid Drugs Sales: by Distribution Channel(K Units)
• Table 143. Cannabinoid Drugs Sales Hospital Pharmacies , by Region K Units (2019-2024)
• Table 144. Cannabinoid Drugs Sales Retail Pharmacies , by Region K Units (2019-2024)
• Table 145. Cannabinoid Drugs Sales Online Pharmacies , by Region K Units (2019-2024)
• Table 146. South America Cannabinoid Drugs Sales, by Country K Units (2019-2024)
• Table 147. South America Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 148. South America Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 149. South America Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 150. South America Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 151. Brazil Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 152. Brazil Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 153. Brazil Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 154. Brazil Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 155. Argentina Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 156. Argentina Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 157. Argentina Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 158. Argentina Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 159. Rest of South America Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 160. Rest of South America Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 161. Rest of South America Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 162. Rest of South America Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 163. Asia Pacific Cannabinoid Drugs Sales, by Country K Units (2019-2024)
• Table 164. Asia Pacific Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 165. Asia Pacific Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 166. Asia Pacific Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 167. Asia Pacific Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 168. China Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 169. China Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 170. China Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 171. China Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 172. Japan Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 173. Japan Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 174. Japan Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 175. Japan Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 176. India Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 177. India Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 178. India Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 179. India Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 180. South Korea Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 181. South Korea Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 182. South Korea Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 183. South Korea Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 184. Taiwan Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 185. Taiwan Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 186. Taiwan Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 187. Taiwan Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 188. Australia Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 189. Australia Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 190. Australia Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 191. Australia Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 192. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 193. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 194. Rest of Asia-Pacific Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 195. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 196. Europe Cannabinoid Drugs Sales, by Country K Units (2019-2024)
• Table 197. Europe Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 198. Europe Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 199. Europe Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 200. Europe Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 201. Germany Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 202. Germany Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 203. Germany Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 204. Germany Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 205. France Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 206. France Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 207. France Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 208. France Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 209. Italy Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 210. Italy Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 211. Italy Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 212. Italy Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 213. United Kingdom Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 214. United Kingdom Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 215. United Kingdom Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 216. United Kingdom Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 217. Netherlands Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 218. Netherlands Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 219. Netherlands Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 220. Netherlands Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 221. Rest of Europe Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 222. Rest of Europe Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 223. Rest of Europe Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 224. Rest of Europe Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 225. MEA Cannabinoid Drugs Sales, by Country K Units (2019-2024)
• Table 226. MEA Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 227. MEA Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 228. MEA Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 229. MEA Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 230. Middle East Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 231. Middle East Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 232. Middle East Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 233. Middle East Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 234. Africa Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 235. Africa Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 236. Africa Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 237. Africa Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 238. North America Cannabinoid Drugs Sales, by Country K Units (2019-2024)
• Table 239. North America Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 240. North America Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 241. North America Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 242. North America Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 243. United States Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 244. United States Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 245. United States Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 246. United States Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 247. Canada Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 248. Canada Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 249. Canada Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 250. Canada Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 251. Mexico Cannabinoid Drugs Sales, by Type K Units (2019-2024)
• Table 252. Mexico Cannabinoid Drugs Sales, by Application K Units (2019-2024)
• Table 253. Mexico Cannabinoid Drugs Sales, by End-users K Units (2019-2024)
• Table 254. Mexico Cannabinoid Drugs Sales, by Distribution Channel K Units (2019-2024)
• Table 255. Cannabinoid Drugs: by Type(USD/Units)
• Table 256. Company Basic Information, Sales Area and Its Competitors
• Table 257. Company Basic Information, Sales Area and Its Competitors
• Table 258. Company Basic Information, Sales Area and Its Competitors
• Table 259. Company Basic Information, Sales Area and Its Competitors
• Table 260. Company Basic Information, Sales Area and Its Competitors
• Table 261. Company Basic Information, Sales Area and Its Competitors
• Table 262. Company Basic Information, Sales Area and Its Competitors
• Table 263. Company Basic Information, Sales Area and Its Competitors
• Table 264. Company Basic Information, Sales Area and Its Competitors
• Table 265. Company Basic Information, Sales Area and Its Competitors
• Table 266. Company Basic Information, Sales Area and Its Competitors
• Table 267. Cannabinoid Drugs: by Type(USD Million)
• Table 268. Cannabinoid Drugs Phytocannabinoids , by Region USD Million (2027-2032)
• Table 269. Cannabinoid Drugs Endocannabinoids , by Region USD Million (2027-2032)
• Table 270. Cannabinoid Drugs Synthetics , by Region USD Million (2027-2032)
• Table 271. Cannabinoid Drugs: by Application(USD Million)
• Table 272. Cannabinoid Drugs Chronic Diseases , by Region USD Million (2027-2032)
• Table 273. Cannabinoid Drugs Anxiety , by Region USD Million (2027-2032)
• Table 274. Cannabinoid Drugs Nausea , by Region USD Million (2027-2032)
• Table 275. Cannabinoid Drugs Others , by Region USD Million (2027-2032)
• Table 276. Cannabinoid Drugs: by End-users(USD Million)
• Table 277. Cannabinoid Drugs Hospitals , by Region USD Million (2027-2032)
• Table 278. Cannabinoid Drugs Clinics , by Region USD Million (2027-2032)
• Table 279. Cannabinoid Drugs Ambulatory Surgical Centers , by Region USD Million (2027-2032)
• Table 280. Cannabinoid Drugs Others , by Region USD Million (2027-2032)
• Table 281. Cannabinoid Drugs: by Distribution Channel(USD Million)
• Table 282. Cannabinoid Drugs Hospital Pharmacies , by Region USD Million (2027-2032)
• Table 283. Cannabinoid Drugs Retail Pharmacies , by Region USD Million (2027-2032)
• Table 284. Cannabinoid Drugs Online Pharmacies , by Region USD Million (2027-2032)
• Table 285. South America Cannabinoid Drugs, by Country USD Million (2027-2032)
• Table 286. South America Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 287. South America Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 288. South America Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 289. South America Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 290. Brazil Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 291. Brazil Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 292. Brazil Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 293. Brazil Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 294. Argentina Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 295. Argentina Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 296. Argentina Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 297. Argentina Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 298. Rest of South America Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 299. Rest of South America Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 300. Rest of South America Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 301. Rest of South America Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 302. Asia Pacific Cannabinoid Drugs, by Country USD Million (2027-2032)
• Table 303. Asia Pacific Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 304. Asia Pacific Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 305. Asia Pacific Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 306. Asia Pacific Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 307. China Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 308. China Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 309. China Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 310. China Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 311. Japan Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 312. Japan Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 313. Japan Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 314. Japan Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 315. India Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 316. India Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 317. India Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 318. India Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 319. South Korea Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 320. South Korea Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 321. South Korea Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 322. South Korea Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 323. Taiwan Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 324. Taiwan Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 325. Taiwan Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 326. Taiwan Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 327. Australia Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 328. Australia Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 329. Australia Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 330. Australia Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 331. Rest of Asia-Pacific Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 332. Rest of Asia-Pacific Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 333. Rest of Asia-Pacific Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 334. Rest of Asia-Pacific Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 335. Europe Cannabinoid Drugs, by Country USD Million (2027-2032)
• Table 336. Europe Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 337. Europe Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 338. Europe Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 339. Europe Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 340. Germany Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 341. Germany Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 342. Germany Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 343. Germany Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 344. France Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 345. France Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 346. France Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 347. France Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 348. Italy Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 349. Italy Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 350. Italy Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 351. Italy Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 352. United Kingdom Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 353. United Kingdom Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 354. United Kingdom Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 355. United Kingdom Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 356. Netherlands Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 357. Netherlands Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 358. Netherlands Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 359. Netherlands Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 360. Rest of Europe Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 361. Rest of Europe Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 362. Rest of Europe Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 363. Rest of Europe Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 364. MEA Cannabinoid Drugs, by Country USD Million (2027-2032)
• Table 365. MEA Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 366. MEA Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 367. MEA Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 368. MEA Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 369. Middle East Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 370. Middle East Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 371. Middle East Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 372. Middle East Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 373. Africa Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 374. Africa Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 375. Africa Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 376. Africa Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 377. North America Cannabinoid Drugs, by Country USD Million (2027-2032)
• Table 378. North America Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 379. North America Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 380. North America Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 381. North America Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 382. United States Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 383. United States Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 384. United States Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 385. United States Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 386. Canada Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 387. Canada Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 388. Canada Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 389. Canada Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 390. Mexico Cannabinoid Drugs, by Type USD Million (2027-2032)
• Table 391. Mexico Cannabinoid Drugs, by Application USD Million (2027-2032)
• Table 392. Mexico Cannabinoid Drugs, by End-users USD Million (2027-2032)
• Table 393. Mexico Cannabinoid Drugs, by Distribution Channel USD Million (2027-2032)
• Table 394. Cannabinoid Drugs Sales: by Type(K Units)
• Table 395. Cannabinoid Drugs Sales Phytocannabinoids , by Region K Units (2027-2032)
• Table 396. Cannabinoid Drugs Sales Endocannabinoids , by Region K Units (2027-2032)
• Table 397. Cannabinoid Drugs Sales Synthetics , by Region K Units (2027-2032)
• Table 398. Cannabinoid Drugs Sales: by Application(K Units)
• Table 399. Cannabinoid Drugs Sales Chronic Diseases , by Region K Units (2027-2032)
• Table 400. Cannabinoid Drugs Sales Anxiety , by Region K Units (2027-2032)
• Table 401. Cannabinoid Drugs Sales Nausea , by Region K Units (2027-2032)
• Table 402. Cannabinoid Drugs Sales Others , by Region K Units (2027-2032)
• Table 403. Cannabinoid Drugs Sales: by End-users(K Units)
• Table 404. Cannabinoid Drugs Sales Hospitals , by Region K Units (2027-2032)
• Table 405. Cannabinoid Drugs Sales Clinics , by Region K Units (2027-2032)
• Table 406. Cannabinoid Drugs Sales Ambulatory Surgical Centers , by Region K Units (2027-2032)
• Table 407. Cannabinoid Drugs Sales Others , by Region K Units (2027-2032)
• Table 408. Cannabinoid Drugs Sales: by Distribution Channel(K Units)
• Table 409. Cannabinoid Drugs Sales Hospital Pharmacies , by Region K Units (2027-2032)
• Table 410. Cannabinoid Drugs Sales Retail Pharmacies , by Region K Units (2027-2032)
• Table 411. Cannabinoid Drugs Sales Online Pharmacies , by Region K Units (2027-2032)
• Table 412. South America Cannabinoid Drugs Sales, by Country K Units (2027-2032)
• Table 413. South America Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 414. South America Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 415. South America Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 416. South America Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 417. Brazil Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 418. Brazil Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 419. Brazil Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 420. Brazil Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 421. Argentina Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 422. Argentina Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 423. Argentina Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 424. Argentina Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 425. Rest of South America Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 426. Rest of South America Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 427. Rest of South America Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 428. Rest of South America Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 429. Asia Pacific Cannabinoid Drugs Sales, by Country K Units (2027-2032)
• Table 430. Asia Pacific Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 431. Asia Pacific Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 432. Asia Pacific Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 433. Asia Pacific Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 434. China Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 435. China Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 436. China Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 437. China Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 438. Japan Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 439. Japan Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 440. Japan Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 441. Japan Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 442. India Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 443. India Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 444. India Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 445. India Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 446. South Korea Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 447. South Korea Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 448. South Korea Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 449. South Korea Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 450. Taiwan Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 451. Taiwan Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 452. Taiwan Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 453. Taiwan Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 454. Australia Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 455. Australia Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 456. Australia Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 457. Australia Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 458. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 459. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 460. Rest of Asia-Pacific Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 461. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 462. Europe Cannabinoid Drugs Sales, by Country K Units (2027-2032)
• Table 463. Europe Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 464. Europe Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 465. Europe Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 466. Europe Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 467. Germany Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 468. Germany Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 469. Germany Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 470. Germany Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 471. France Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 472. France Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 473. France Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 474. France Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 475. Italy Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 476. Italy Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 477. Italy Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 478. Italy Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 479. United Kingdom Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 480. United Kingdom Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 481. United Kingdom Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 482. United Kingdom Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 483. Netherlands Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 484. Netherlands Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 485. Netherlands Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 486. Netherlands Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 487. Rest of Europe Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 488. Rest of Europe Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 489. Rest of Europe Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 490. Rest of Europe Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 491. MEA Cannabinoid Drugs Sales, by Country K Units (2027-2032)
• Table 492. MEA Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 493. MEA Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 494. MEA Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 495. MEA Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 496. Middle East Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 497. Middle East Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 498. Middle East Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 499. Middle East Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 500. Africa Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 501. Africa Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 502. Africa Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 503. Africa Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 504. North America Cannabinoid Drugs Sales, by Country K Units (2027-2032)
• Table 505. North America Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 506. North America Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 507. North America Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 508. North America Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 509. United States Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 510. United States Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 511. United States Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 512. United States Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 513. Canada Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 514. Canada Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 515. Canada Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 516. Canada Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 517. Mexico Cannabinoid Drugs Sales, by Type K Units (2027-2032)
• Table 518. Mexico Cannabinoid Drugs Sales, by Application K Units (2027-2032)
• Table 519. Mexico Cannabinoid Drugs Sales, by End-users K Units (2027-2032)
• Table 520. Mexico Cannabinoid Drugs Sales, by Distribution Channel K Units (2027-2032)
• Table 521. Cannabinoid Drugs: by Type(USD/Units)
• Table 522. Research Programs/Design for This Report
• Table 523. Key Data Information from Secondary Sources
• Table 524. Key Data Information from Primary Sources

• Figure 1. Porters Five Forces
• Figure 2. Supply/Value Chain
• Figure 3. PESTEL analysis
• Figure 4. Global Cannabinoid Drugs: by Type USD Million (2019-2024)
• Figure 5. Global Cannabinoid Drugs: by Application USD Million (2019-2024)
• Figure 6. Global Cannabinoid Drugs: by End-users USD Million (2019-2024)
• Figure 7. Global Cannabinoid Drugs: by Distribution Channel USD Million (2019-2024)
• Figure 8. South America Cannabinoid Drugs Share (%), by Country
• Figure 9. Asia Pacific Cannabinoid Drugs Share (%), by Country
• Figure 10. Europe Cannabinoid Drugs Share (%), by Country
• Figure 11. MEA Cannabinoid Drugs Share (%), by Country
• Figure 12. North America Cannabinoid Drugs Share (%), by Country
• Figure 13. Global Cannabinoid Drugs: by Type K Units (2019-2024)
• Figure 14. Global Cannabinoid Drugs: by Application K Units (2019-2024)
• Figure 15. Global Cannabinoid Drugs: by End-users K Units (2019-2024)
• Figure 16. Global Cannabinoid Drugs: by Distribution Channel K Units (2019-2024)
• Figure 17. South America Cannabinoid Drugs Share (%), by Country
• Figure 18. Asia Pacific Cannabinoid Drugs Share (%), by Country
• Figure 19. Europe Cannabinoid Drugs Share (%), by Country
• Figure 20. MEA Cannabinoid Drugs Share (%), by Country
• Figure 21. North America Cannabinoid Drugs Share (%), by Country
• Figure 22. Global Cannabinoid Drugs: by Type USD/Units (2019-2024)
• Figure 23. Global Cannabinoid Drugs share by Players 2024 (%)
• Figure 24. Global Cannabinoid Drugs share by Players (Top 3) 2024(%)
• Figure 25. Global Cannabinoid Drugs share by Players (Top 5) 2024(%)
• Figure 26. BCG Matrix for key Companies
• Figure 27. Echo Pharmaceuticals B.V. (Netherlands) Revenue, Net Income and Gross profit
• Figure 28. Echo Pharmaceuticals B.V. (Netherlands) Revenue: by Geography 2024
• Figure 29. Mandara Pharma (Canada) Revenue, Net Income and Gross profit
• Figure 30. Mandara Pharma (Canada) Revenue: by Geography 2024
• Figure 31. GW Pharmaceuticals, plc (United Kingdom) Revenue, Net Income and Gross profit
• Figure 32. GW Pharmaceuticals, plc (United Kingdom) Revenue: by Geography 2024
• Figure 33. Nexien BioPharma (United States) Revenue, Net Income and Gross profit
• Figure 34. Nexien BioPharma (United States) Revenue: by Geography 2024
• Figure 35. BOL Pharma (Israel) Revenue, Net Income and Gross profit
• Figure 36. BOL Pharma (Israel) Revenue: by Geography 2024
• Figure 37. CURE Pharmaceutical Holding Corp. (United States) Revenue, Net Income and Gross profit
• Figure 38. CURE Pharmaceutical Holding Corp. (United States) Revenue: by Geography 2024
• Figure 39. RAMM Pharma (Canada) Revenue, Net Income and Gross profit
• Figure 40. RAMM Pharma (Canada) Revenue: by Geography 2024
• Figure 41. Greenwich Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
• Figure 42. Greenwich Biosciences, Inc. (United States) Revenue: by Geography 2024
• Figure 43. UNIVO Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
• Figure 44. UNIVO Pharmaceuticals (Israel) Revenue: by Geography 2024
• Figure 45. InMed Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
• Figure 46. InMed Pharmaceuticals (Canada) Revenue: by Geography 2024
• Figure 47. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
• Figure 48. Abbott Laboratories (United States) Revenue: by Geography 2024
• Figure 49. Global Cannabinoid Drugs: by Type USD Million (2027-2032)
• Figure 50. Global Cannabinoid Drugs: by Application USD Million (2027-2032)
• Figure 51. Global Cannabinoid Drugs: by End-users USD Million (2027-2032)
• Figure 52. Global Cannabinoid Drugs: by Distribution Channel USD Million (2027-2032)
• Figure 53. South America Cannabinoid Drugs Share (%), by Country
• Figure 54. Asia Pacific Cannabinoid Drugs Share (%), by Country
• Figure 55. Europe Cannabinoid Drugs Share (%), by Country
• Figure 56. MEA Cannabinoid Drugs Share (%), by Country
• Figure 57. North America Cannabinoid Drugs Share (%), by Country
• Figure 58. Global Cannabinoid Drugs: by Type K Units (2027-2032)
• Figure 59. Global Cannabinoid Drugs: by Application K Units (2027-2032)
• Figure 60. Global Cannabinoid Drugs: by End-users K Units (2027-2032)
• Figure 61. Global Cannabinoid Drugs: by Distribution Channel K Units (2027-2032)
• Figure 62. South America Cannabinoid Drugs Share (%), by Country
• Figure 63. Asia Pacific Cannabinoid Drugs Share (%), by Country
• Figure 64. Europe Cannabinoid Drugs Share (%), by Country
• Figure 65. MEA Cannabinoid Drugs Share (%), by Country
• Figure 66. North America Cannabinoid Drugs Share (%), by Country
• Figure 67. Global Cannabinoid Drugs: by Type USD/Units (2027-2032)

• Echo Pharmaceuticals B.V. (Netherlands)
• Mandara Pharma (Canada)
• GW Pharmaceuticals, plc (United Kingdom)
• Nexien BioPharma (United States)
• BOL Pharma (Israel)
• CURE Pharmaceutical Holding Corp. (United States)
• RAMM Pharma (Canada)
• Greenwich Biosciences, Inc. (United States)
• UNIVO Pharmaceuticals (Israel)
• InMed Pharmaceuticals (Canada)
• Abbott Laboratories (United States)

Ilesol Pharmaceuticals d.o.o. (Croatia) , Valeant Pharmaceuticals International (Canada) , Indevus Pharmaceuticals Inc. (United States)